Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBT6290 Alone and with Pembrolizumab in Nectin-4 Expressing Advanced Solid Tumors
NCT05234606Phase 2Withdrawn
- Sponsor
- Silverback Therapeutics
- Start
- Mar 2022
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 2, open-label trial of SBT6290 in urothelial carcinoma (UC), triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) and 2 more, sponsored by Silverback Therapeutics. Primary endpoints: Number of Participants With Dose Limiting Toxicities at 28 days, Number of Participants With Treatment-emergent Adverse Events at 2 years and 2 more. Planned start Mar 2022; status: withdrawn.
02
Drugs
SBT6290
03
Conditions
urothelial carcinoma (UC)triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)hormone receptor-positive/HER2-negative breast cancer
Beyond the preview
Go deeper on NCT05234606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05234606.